Edwards Lifesciences Corp. is discontinuing its Centera self-expanding transcatheter aortic valve replacement (TAVR) system to focus entirely on its successful Sapien 3 and Sapien 3 Ultra balloon-expandable TAVR systems.
“While the Centera valve has demonstrated excellent clinical outcomes and is performing well for patients, the time and resources required to optimize deliverability as well as expanding the indications to...